Intrathecal Gene Therapy for Giant Axonal Neuropathy
New England Journal of Medicine · 21.03.2024 · 390 (12) · 1092-1104
DOI: 10.1056/nejmoa2307952 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 21.03.2024. Verfasst von Diana X Bharucha-Goebel und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the Neuromuscular and Neurogenetic Disorders of Childhood Section (D.X.B.-G., J.J.T., D.S., A.R.F., P.M., C.G.B), National Institute of Neurolog…. Hauptthemen laut MEDLINE: Genetic Therapy, Giant Axonal Neuropathy, Gene Transfer Techniques. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NINDS NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Giant axonal neuropathy is a rare, autosomal recessive, pediatric, polysymptomatic, neurodegenerative disorder caused by biallelic loss-of-function variants in GAN, the gene encoding gigaxonin. METHODS: We conducted an intrathecal dose-escalation study of scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy containing the GAN transgene) in children with giant axonal neuropathy. Safety was the primary end point. The key secondary clinical end point was at least a 95% posterior probability of slowing the rate of change (i.e., slope) in the 32-item Motor Function Measure total percent score at 1 year after treatment, as compared with the pretreatment slope. RESULTS: One of four intrathecal doses of scAAV9/JeT-GAN was administered to 14 participants - 3.5×1013 total vector genomes (vg) (in 2 participants), 1.2×1014 vg (in 4), 1.8×1014 vg (in 5), and 3.5×1014 vg (in 3). During a median observation period of 68.7 months (range, 8.6 to 90.5), of 48 serious adverse events that had occurred, 1 (fever) was possibly related to treatment; 129 of 682 adverse events were possibly related to treatment. The mean pretreatment slope in the total cohort was -7.17 percentage points per year (95% credible interval, -8.36 to -5.97). At 1 year after treatment, posterior mean changes in slope were -0.54 percentage points (95% credible interval, -7.48 to 6.28) with the 3.5×1013-vg dose, 3.23 percentage points (95% credible interval, -1.27 to 7.65) with the 1.2×1014-vg dose, 5.32 percentage points (95% credible interval, 1.07 to 9.57) with the 1.8×1014-vg dose, and 3.43 percentage points (95% credible interval, -1.89 to 8.82) with the 3.5×1014-vg dose. The corresponding posterior probabilities for slowing the slope were 44% (95% credible interval, 43 to 44); 92% (95% credible interval, 92 to 93); 99% (95% credible interval, 99 to 99), which was above the efficacy threshold; and 90% (95% credible interval, 89 to 90). Between 6 and 24 months after gene transfer, sensory-nerve action potential amplitudes increased, stopped declining, or became recordable after being absent in 6 participants but remained absent in 8. CONCLUSIONS: Intrathecal gene transfer with scAAV9/JeT-GAN for giant axonal neuropathy was associated with adverse events and resulted in a possible benefit in motor function scores and other measures at some vector doses over a year. Further studies are warranted to determine the safety and efficacy of intrathecal AAV-mediated gene therapy in this disorder. (Funded by the National Institute of Neurological Disorders and Stroke and others; ClinicalTrials.gov number, NCT02362438.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Neuromuscular and Neurogenetic Disorders of Childhood Section (D.X.B.-G., J.J.T., D.S., A.R.F., P.M., C.G.B), National Institute of Neurological Disorders and Stroke (G.N., T.L., J.D.H.), the Rehabilitation Med…
Förderung
- NIAMS NIH HHS
- NINDS NIH HHS
- Intramural NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Child Neurology Society
- American Society of Gene and Cell Therapy
- Hannah’s Hope Fund
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Bharucha-Goebel, D. X., Todd, J. J., Saade, D., Norato, G., Jain, M., Lehky, T., Bailey, R. M., Chichester, J. A., Calcedo, R., Armao, D., Foley, A. R., Mohassel, P., Tesfaye, E., Carlin, B. P., Seremula, B., Waite, M., Zein, W. M., Huryn, L. A., Crawford, T. O., …, & GAN Trial Team (2024). Intrathecal Gene Therapy for Giant Axonal Neuropathy. New England Journal of Medicine, 390(12), 1092-1104. https://doi.org/10.1056/nejmoa2307952
Vancouver
Bharucha-Goebel DX, Todd JJ, Saade D, Norato G, Jain M, Lehky T, et al. Intrathecal Gene Therapy for Giant Axonal Neuropathy. New England Journal of Medicine. 2024;390(12):1092-1104. doi:10.1056/nejmoa2307952
BibTeX
@article{BharuchaGoebel2024,
author = {Bharucha-Goebel, Diana X and Todd, Joshua J and Saade, Dimah and Norato, Gina and Jain, Minal and Lehky, Tanya and Bailey, Rachel M and Chichester, Jessica A and Calcedo, Roberto and Armao, Diane and Foley, A Reghan and Mohassel, Payam and Tesfaye, Eshetu and Carlin, Bradley P and Seremula, Beth and Waite, Melissa and Zein, Wadih M and Huryn, Laryssa A and Crawford, Thomas O and Sumner, Charlotte J and Hoke, Ahmet and Heiss, John D and Charnas, Lawrence and Hooper, Jody E and Bouldin, Thomas W and Kang, Elizabeth M and Rybin, Denis and Gray, Steven J and Bönnemann, Carsten G and GAN Trial Team, GAN Trial Team},
title = {Intrathecal Gene Therapy for Giant Axonal Neuropathy},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {12},
pages = {1092--1104},
doi = {10.1056/nejmoa2307952}
}
EUVIMED